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1Abstract12
Objective To determine the incidence of new primary malignancies after adult-type3
granulosa cell tumor (AGCT), and the incidence of AGCT after breast and uterine4
cancer using nationwide population-based registry data.5
Methods We identified all patients diagnosed with AGCT in 1968-2013 from the6
Finnish Cancer Registry (n=986). The number of subsequent primary malignancies7
among women with AGCT, and the number of AGCTs in women with previous8
breast or uterine cancer were compared with the expected number of cases, and9
expressed as Standardized Incidence Ratios (SIRs).10
Results There were 122 cases of subsequent cancers diagnosed at least six months11
after the primary diagnosis of AGCT (SIR 1.09, 95% CI 0.91-1.3). Particularly, the12
observed number of cancers of the soft tissue (SIR 4.13, 95% CI 1.33-12.8), thyroid13
(SIR 3.42, 95% CI 1.54-7.62), and leukemia (SIR 2.67, 95% CI 0.98-5.82) exceeded14
the number of expected cases. The SIR for breast cancers after AGCT was 1.26 (95%15
CI 0.92-1.73), and the SIR for AGCT after breast cancer 1.59 (95% CI 1.04-2.29).16
The risk for subsequent AGCT was more than two-fold in breast cancer patients less17
than 50 years of age, and over 15 years after primary diagnosis.18
Conclusions There is an increased risk for thyroid and soft tissue cancer as well as19
leukemia after AGCT, which may be associated with late effects of carcinogenic20
treatments and possibly shared risk factors. After breast cancer, the risk for AGCT21
was higher, which may indicate shared hormonal etiology.222324
2Introduction2526
Adult type-granulosa cell tumors of the ovary (AGCTs) account for 5% of all27
ovarian neoplasms, and constitute the majority of sex cord-stromal tumors1. The28
recently reported age-adjusted (World Standard) incidence rates (truncated to age29
categories 20 years or older) of AGCT average around 0.6-0.8/100,000 women, and30
peak after menopause 2.  AGCTs are characterized by their estrogen-secreting ability,31
although it has been estimated that approximately 30% of these tumors do not secrete32
estradiol, likely due to lack of theca cells in the tumor stroma1. A single somatic point33
mutation in the transcription factor FOXL2 (402C-G) is the pathognomonic molecular34
feature for AGCTs3. Otherwise, the etiological factors remain unknown, although35
some studies have suggested a possible hormonal background for these tumors4, 5.36
According to current knowledge, there is no hereditary predisposition for the37
development of AGCT.38
The diagnosis is usually made at an early stage, partly due to symptoms39
related to hormone secretion, and the disease tends to run an indolent course.40
Excessive exposure to tumor-derived estrogen among these patients leads to an41
increased risk of concomitant endometrial pathology and endometrial cancer 6-9.42
There are, however, only a few studies focusing on other primary malignancies in43
women with AGCT 10, 11. In general, the risk of other primary malignancies after44
ovarian cancer is associated with either inherent genetic or lifestyle-related extrinsic45
risk factors, or carcinogenic treatment regimens 12-14. As other, particularly endocrine-46
related cancers may share etiological factors with AGCTs, it is of interest to study the47
potential association of these cancers, especially breast and uterine cancer.  The object48
3of our study was to evaluate the incidence of all other primary cancers after AGCT, as49
well the incidence of AGCT after breast or uterine cancer.5051
Materials and methods5253
In this retrospective cohort study, we identified all patients diagnosed with54
AGCT in Finland during 1968-2013 from the Finnish Cancer Registry (FCR). The55
FCR is a high-quality, population-based registry relying on unique personal identity56
codes. The personal identity code is a specific means of identification, which remains57
unchanged throughout the person’s lifetime, and has been used in Finland since the58
1960s. Physicians, hospitals, and pathology and hematology laboratories in Finland59
are obliged to report all malignant tumors to the FCR, resulting in a nearly complete60
registration of all cancer cases15. Information on vital status and emigration was61
obtained from the Population Register Center, which is directly linked to the FCR62
information.63
AGCTs were retrieved from the registry applying the ICD topography code64
C56.9 with morphology codes M8620/1, 8620/3, 8621/1, and 8621/3. The incidence65
rates of AGCT during the follow-up period were calculated, and adjusted for age to66
the World Standard Population. All patients were followed up for second primary67
cancer from the date of first diagnosis (1968-2013) to the date of death, date of68
migration, or until December 31st, 2013.  In order to identify concomitant cancers and69
surveillance bias, the analyses were carried out in two subgroups: 1) all subsequent70
tumors after AGCT, and 2) all subsequent tumors except those occurring within six71
months after AGCT. Subsequent primary tumors were grouped in 18 categories based72
on cancer site, and included ICD-codes C00-96, D32-33, D42-43, D45-47, and D7673
4(mouth/pharynx, digestive organs, respiratory organs, breast, female genitalia, urinary74
organs, melanoma of the skin, skin (other than melanoma), eye, thyroid gland, other75
endocrine glands, bone, soft tissues, mesothelioma, autonomic nervous system,76
brain/central nervous system, lymphoid/hematopoietic tissue, other/not defined). The77
number of new primary malignant tumors among women with previous AGCT was78
compared with the expected number of cases calculated from the accumulated person-79
years and incidence rates for the national population, stratified by age and year of80
diagnosis.81
Secondly, we analyzed the number of subsequent AGCTs in women with a82
first primary breast or uterine cancer (ICD C54 and C50), and compared it with the83
expected number of AGCTs. These analyses were likewise performed separately on84
all subsequent AGCTs as well as those occurring within 6 months of the primary85
cancer diagnoses. The ratio of observed to expected cases was defined as the86
Standardized Incidence Ratio (SIR), and 95% confidence intervals (CI) were87
calculated.  The SIRs were also stratified for time since first primary cancer diagnosis88
(0-4 years, 5-14 and 15+ years after the diagnosis of first primary tumor), for age at89
the first primary cancer diagnosis (<50 or 50 years or older), and in breast cancer also90
for the invasion status (localized vs. non-localized).91
The ethics committee of Helsinki University Hospital (HUH) and the National92
Supervisory Authority for Welfare and Health approved the study.939495
Results9697
5In 1968-2013, a total of 986 women in Finland were diagnosed with AGCT.98
The age-adjusted (World Standard) incidence varied between 0.4 and 0.9 per 100,00099
women, with approximately 20 cases each year (Figure 1).  The logarithmic trend line100
suggests a decreasing trend in the incidence of AGCT over the 45-year study period.101
After the diagnosis of AGCT, 122 cases of new primary malignant tumors102
were recorded, resulting in a 12.4% rate of second malignancies among AGCT103
patients. The expected number was 111.7 (SIR 1.09, 95% CI 0.91-1.3) (Table 1).  If104
also cancers diagnosed within six months of AGCT were included, the total rate was105
13.9% and SIR 1.19 (95% CI 1-1.41, p=0.04). The SIR for these cancers only was106
5.00 (95% CI 2.80-8.23). The median interval between the diagnosis of AGCT and107
second primary tumor was 19.2 years (range 0.02-45.6 years). In a minimum time of108
six months from the primary cancer diagnosis, the observed number of thyroid cancer,109
soft tissue cancer, and leukemia exceeded the number of expected cases significantly110
(Table 1). The SIRs were also elevated for cancers of the oropharynx, breast, urinary111
organs, skin (non-melanoma), and mesothelioma, but not significantly (Table 1).112
There were less than expected cancer cases in the uterine corpus and ovaries. For all113
subsequent cancers, the SIRs stratified for follow-up time were 0.75 for 0.5-4 years114
(95% CI 0.45-1.15), 0.98 for 5-14 years (95% CI 0.72-1.30), and 1.40 (95% CI 1.07-115
1.78) for more than 15 years after diagnosis of AGCT.  The SIR was higher for116
patients who were less than 50 years of age at primary diagnosis (SIR 1.31, 95% CI117
0.96-1.75).  The results were largely similar when also second primary cancer cases118
diagnosed within six months after AGCT were included, with the exception of uterine119
cancer.120
The SIR for breast cancer after AGCT was 1.4 after at least five years of121
primary cancer diagnosis (Table 2). Subsequent breast cancer was somewhat more122
6common in patients who were at least 50 years old at the time of AGCT diagnosis123
(SIR 1.31, 95% CI 0.86-1.91).  The SIR was only elevated in localized breast cancer124
(SIR 1.36, 95% CI 0.86-2.02), as opposed to non-localized breast cancer (SIR 0.83,125
95% CI 0.42-1.46). In patients who had breast cancer diagnosed primarily, there were126
25 cases of subsequent AGCTs during follow-up (Table 3). The SIR for AGCT after127
breast cancer was 1.59 (95% CI 1.04-2.29), and increased with time since breast128
cancer diagnosis to 2.28 (95% CI 0.98-4.41) in the follow-up category of 15 years or129
more. For age below 50 years at breast cancer diagnosis the SIR was 2.10 (95 % CI130
1.09-3.59).131
From the cancers diagnosed within six months of AGCT, uterine cancer132
accounted for 33% (n=5), digestive organs 27% (n=4), and breast cancer 13% (n=2)133
of these cases.  Other malignancies reported within this follow-up period included134
cancers of the urinary tract, and lymphoid/hematopoietic tissue.  After uterine cancer,135
AGCT was diagnosed in 20 women within six months (SIR 4.99, 95% CI 3.18-7.37),136
whereas two women developed AGCT more than 6 months after primary uterine137
cancer diagnosis. All women with uterine cancer and subsequent AGCT were at least138
50 years of age at the time of the uterine cancer diagnosis (SIR 6.21, 95% CI 4.09-139
9.42).140141
Discussion142143
The indolent course, relatively low disease-related mortality and estrogen-144
secreting capability of AGCT result in a clinically relevant lifetime risk for145
developing a second primary cancer. On the other hand, the etiological factors of146
AGCT are largely unknown, and a common predisposing factor may exist behind147
7AGCT and other hormone-related cancers.  To our knowledge, this is the largest and148
first study since Björkholm et al. in 198011 to analyze all second primary malignancies149
among AGCT patients. In our study, women with AGCT had a 9% increased risk of150
developing a new primary malignancy as compared with the general population. If151
cancers diagnosed within six months after the primary tumor were included, the risk152
was significantly increased by 19%. The large difference in these figures is mainly153
explained by the presence of concomitant endometrial cancer, but the significant154
number of cancers of the digestive organs diagnosed within six months of AGCT155
most likely also reflects the increased surveillance among cancer patients in general.156
Two recent publications have described the incidence of endometrial cancer157
and breast cancer among patients with AGCT 6, 10. Van Meurs et al. found a 6% rate158
of endometrial cancer concomitant with the diagnosis of AGCT, but no increased risk159
for endometrial abnormalities in the median follow-up time of 10 years after AGCT160
for patients not having undergone hysterectomy6. Other population-based studies have161
reported 5-8% rates of concomitant endometrial cancer 8, 9, 11, and we reported similar162
rates in a large, single-institute patient cohort16. In the current population-based163
registry cohort, the rate was 2.5% when patients diagnosed primarily with either164
AGCT or uterine cancer and a subsequent uterine cancer or AGCT within six months165
of primary diagnosis were included. This relatively low rate may reflect a proportion166
of previously hysterectomized patients, since they could not be excluded from the167
original cancer registry data. This would also explain the higher incidence in hospital-168
based cohorts, as solely patients with endometrial sample available have been169
evaluated.170
We found an increased risk for breast cancer both before and after diagnosis of171
AGCT, although the risk was significant only before AGCT. This is a similar finding172
8to the smaller Danish, Israeli and US studies where the rate of breast cancer among173
AGCT patients was 5-10% 9, 10, 17. In our study, the rate of breast cancer was 6.9%174
among all women with AGCT. After AGCT, the risk was confined to localized breast175
cancers, which may indicate towards surveillance bias, i.e. the increased frequency176
and intensity of clinical follow-up and examination among patients with previously177
diagnosed cancer. There was a relatively long latency between breast cancer and178
AGCT regardless of which cancer was the first primary tumor, which does not179
support genetic susceptibility. AGCT is neither associated with any of the known180
predisposing mutations to breast cancer such as BRCA1 and BRCA2 mutations, nor is181
the FOXL2 mutation pathognomonic to AGCT present in breast carcinoma 1, 18.  In182
the present study, the risk for subsequent AGCT in breast cancer patients was183
significantly increased in women who were younger than 50 years at primary184
diagnosis, which probably reflects the long follow-up time, as the latency between the185
cancers was also long. Shared etiological factors such as obesity, parity, and hormonal186
environment offer a possible explanation for the increased incidence of breast cancer187
and AGCT among same women. Obesity represents a hyperestrogenic state and is a188
known risk factor for breast cancer19, and has been suggested as a risk factor for189
AGCT4. In post-menopausal women, breast cancer risk is around twice as high in190
those with the highest sex hormone levels compared to those with the lowest20. Parity,191
on the other hand, is a protective factor in both breast and ovarian cancer 21, 22.192
The effects of primary cancer treatment may influence the development of193
second primary AGCT. Selective estrogen receptor modulators (SERMs) such as194
tamoxifen are used to treat hormone-receptor positive breast cancer, and three case195
reports have linked antecedent tamoxifen use with the development of AGCT23-25.196
Furthermore, aromatase inhibitors such as letrozole are used in the treatment of both197
9postmenopausal breast cancer and AGCT26, 27. However, further evidence is198
warranted to establish a causal link between hormonal breast cancer treatment and the199
development of AGCT.200
Similarly to an earlier study, we found an increased risk for thyroid cancer201
among patients with previous AGCT, but it should be noted that the number of cases202
is rather small in both studies11. It has been proposed that female hormones,203
reproductive factors, and obesity also play a role in thyroid cancer pathogenesis, but204
there are no consistent data linking ovarian and thyroid cancer28, 29. DICER1 germline205
mutation carriers have a predisposition to both thyroid cancer and sex cord-stromal,206
particularly Sertoli-Leydig cell tumors30, 31. Cancer registry data are not, however,207
molecularly validated, and there is a possibility that some of the tumors identified as208
AGCT may actually represent other sex cord-stromal tumors.209
We also found significantly increased SIRs for soft tissue cancer and leukemia210
after AGCT. The development of secondary soft tissue sarcoma is strongly associated211
with radiation exposure from radiotherapy, especially after breast cancer32, 33. No212
association between female reproductive factors and the development of soft tissue213
cancer has been detected, but the studies in this field are scarce34. As nowadays214
radiotherapy is rarely used in the treatment of AGCT, the increased SIR for soft tissue215
cancer is most likely related to shared risk factors. Furthermore, radiotherapy for216
ovarian cancer is known to be associated with bladder carcinoma, but in our series,217
the SIR for bladder cancer was not significantly elevated after AGCT35. Adjuvant218
therapy is used in the management of metastatic or recurrent AGCT, and presently219
consists of platinum-based chemotherapeutic agents or more recently, hormonal220
treatments26, 36. Late effects of chemotherapy may include increased risk for leukemia,221
and most likely explains the high incidence of this cancer among patients with222
10
previous AGCT12, 14.  Two large population-based studies on second malignancies223
after ovarian cancer of any type both reported significantly elevated SIRs for cancers224
of the colon, rectum, lung, breast, bladder, and thyroid, as well as for leukemia, and225
the risk for subsequent cancer development was associated with older age, chemo-226
and radiotherapy12, 35.227
This is the largest study to date in analyzing the risk for other primary228
malignancies associated with AGCT. The strengths of this study are the reliable and229
comprehensive cancer registry incidence data, and the long observation period of over230
40 years. The rarity and the lack of molecular validation of AGCT, as well as of231
individual data such as parity, BMI, or use of hormonal therapies are limiting factors232
in this analysis.233
In conclusion,  we found a slightly elevated risk for overall second234
malignancy, particularly thyroid and soft tissue cancer, and leukemia. Partly these235
excesses may result from carcinogenic treatments for AGCT. The increased incidence236
of AGCT and breast cancer among the very same patients may indicate shared237
hormonal etiology. Earlier studies have concluded that breast cancer patients have a238
higher incidence of second primary ovarian cancer, particularly when diagnosed239
before 50 years of age; this patient group might benefit from regular gynecological240
surveillance37-39.  This seems to be true also for AGCT after breast cancer, which241
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Figure legends376377
Figure 1. Incidence of adult-type ovarian granulosa cell tumors (AGCTs) in Finland378
in 1968-2013, with a logarithmic trend line (dotted).379380381382383384
Table 1. Risk of subsequent primary malignancies among Finnish women with previous adult-type
ovarian granulosa cell tumor (AGCT) in 1968-2013, by site.
Second primary tumor site Observed Expected  SIR 95% CI p-value
All 137 114.7 1.19 1-1.41 0.04
All, diagnosis within 6 months of AGCT  15 3.00 5.00 2.80-8.23 <0.001
All, diagnosis > 6 months after AGCT 122 111.7 1.09 0.91-1.3 0.33
Mouth, pharynx 3 1.7 1.76 0.57-5.45 0.33
Digestive organs 24 25.7 0.93 0.63-1.39 0.74
Respiratory organs 5 6.3 0.79 0.33-1.90 0.60
Skin, melanoma 3 3.0 0.99 0.32-3.06 0.98
Skin, non-melanoma 9 4.8 1.86 0.97-3.58 0.06
Soft tissues 3 0.7 4.13 1.33-12.8 0.01
Breast 38 30.2 1.26 0.92-1.73 0.15
Female genitalia 5 14.3 0.35 0.15-0.84 0.02
           Corpus uteri 0 7.1 0.00 0.00-0.52 0.01
           Ovary 1 4.3 0.23 0.01-1.30 0.18
           Cervix uteri 2 1.3 1.49 0.18-5.38 0.89
           Other 2 1.5 1.38 0.17-4.98 0.97
Urinary organs 8 5.6 1.43 0.71-2.86 0.31
           Bladder and urinary tract 3 2.4 1.27 0.26-3.73 0.92
Brain, central nervous system 3 3.9 0.76 0.25-2.36 0.64
Thyroid gland 6 1.8 3.42 1.54-7.62 0.003
Lymphoid and hematopoietic tissue 11 9.6 1.15 0.64-2.07 0.65
          Leukemia 6 2.2 2.67 0.98-5.82 0.03
Other or not defined 3 3.4 0.88 0.28-2.72 0.82
SIR= standardized incidence ratio, CI = confidence interval. Sites with < 3 observed cases are
excluded, with the exception of cancers of the female genitalia.
Table 2. Risk of subsequent breast cancer among Finnish women with previous adult-
type granulosa cell tumor (AGCT) in 1968-2013, by age at and time since AGCT
diagnosis, and breast cancer invasion.
Observed Expected  SIR 95% CI p-value
All 40 31 1.29 0.93-1.73 0.11
All, diagnosis > 6 months
after AGCT
38 30.2 1.26 0.9-1.7 0.15
Follow-up time (years)
          0-4 6 6.9 0.87 0.34-1.76 0.73
          5-14 17 12.3 1.38 0.82-2.15 0.18
          ≥15 15 10.9 1.37 0.79-2.19 0.22
Age at AGCT diagnosis
          <50 14 11.9 1.18 0.66-1.91 0.54
          ≥50 24 18.3 1.31 0.86-1.91 0.18
Breast cancer invasion1
          Localized 21 15.5 1.36 0.86-2.02 0.16
          Non-localized 10 12.0 0.83 0.42-1.46 0.56
AGCT= adult-type ovarian granulosa cell tumor, SIR= standardized incidence ratio, CI
= confidence interval.
1Invasion status unknown in seven cases
Table 3. Risk of subsequent adult-type granulosa cell tumors (AGCTs) among Finnish
women with breast cancer in 1968-2013, by age at and time since breast cancer
diagnosis.
Observed Expected SIR 95% CI p-value
All 28 16.6 1.69 1.14-2.4 0.006
All, diagnosis > 6 months after
breast cancer
25 15.7 1.59 1.04-2.29 0.02
Follow-up time (years)
          0-4 8 5.9 1.35 0.62-2.52 0.39
          5-14 10 6.8 1.48 0.74-2.59 0.22
          ≥15 7 3.1 2.28 0.98-4.41 0.03
Age at breast cancer diagnosis
          <50 11 5.2 2.10 1.09-3.59 0.01
          ≥50 14 10.5 1.33 0.75-2.16 0.28
SIR= standardized incidence ratio, CI = confidence interval.
Figure 1. Incidence of adult-type ovarian granulosa cell tumors (AGCTs) in Finland in 1968-2013,
with a logarithmic trend line (dotted).
